产品封面图
文献支持

Recombinant Human Coagulation

Factor VIIa
收藏
  • ¥2415 - 53130
  • Prospecbio
  • 以色列
  • pro-331
  • 2025年07月13日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      for future use below -18°C

    • 保质期

      See instructions

    • 英文名

      F7

    • 库存

      常规产品有备货

    • 供应商

      上海经科化学科技有限公司

    • CAS号

    • 规格

      10ug/50ug/1mg

    规格:10ug产品价格:¥2415.0
    规格:50ug产品价格:¥6200.0
    规格:1mg产品价格:¥53130.0

    产品细节图片1

    CATALOGUE NUMBER

    PRO-331

    SYNONYMS

    Coagulation factor VII, EC 3.4.21.21, Serum prothrombin conversion accelerator, SPCA, Proconvertin, Eptacog alfa, F7.

    INTRODUCTION

    Coagulation factor VII is a vitamin K-dependent factor which is essential for hemostasis. It circulates in the blood as a zymogen which is later converted to an active form by factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of factor VII, a heavy chain with a catalytic domain and a light chain with 2 EGF-like domains are generated, and the two chains are held together by a disulfide bond. The presence of factor III and calcium ions further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Alternative splicing of factor VII results in 2 transcripts. Defects in coagulation factor VII can cause coagulopathy. Coagulation factor VII initiates the extrinsic pathway of blood coagulation. Minor proteolysis converts factor VII to factor VIIa by factors Xa, XIIa, IXa, or thrombin. Factor VIIa also converts factor IX to factor IXa in the presence of tissue factor and calcium.

    DESCRIPTION

    Factor VIIa Human Recombinant produced in BHK is a glycosylated polypeptide two-chain dimer consisting of 406 amino acids with a molecular weight of 50kD.
    The Factor-VIIa is purified by proprietary chromatographic techniques.

    SOURCE

    BHK cells (Baby Hamster Kidney Cells).

    PHYSICAL APPEARANCE

    Sterile Filtered White lyophilized (freeze-dried) powder.

    FORMULATION

    The protein 1 mg/ml was lyophilized after from a sterile solution containing 10mg sucrose pH-6.

    SOLUBILITY

    It is recommended to reconstitute the lyophilized Factor-VIIa in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

    STABILITY

    Lyophilized Factor-VIIa although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Factor-VIIa should be stored at 4°C between 2-7 days and for future use below -18°C.
    Please prevent freeze-thaw cycles.

    PURITY

    Greater than 98.0% as determined by analysis by SDS-PAGE.

    BIOLOGICAL ACTIVITY

    The potency per mg was tested and found to be 50,000Units/mg.

    SAFETY DATA SHEET

    SDS

    USAGE

    Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    Factor VIIa Human Recombinant produced in BHK is a glycosylated polypeptide two-chain dimer consisting of 406 amino acids with a molecular weight of 50kD.
    The Factor-VIIa is purified by proprietary chromatographic techniques.

    相关实验
    • Tissue Factor/VIIa in Thrombosis and Cancer

      Tissue factor (TF) is a transmembrane glycoprotein that functions as a receptor and cofactor for activated factor VII (factor VIIa) to initiate blood coagulation. Although TF has been characterized best for its role in blood coagulation

    • Use of Human Hepatocytes to Investigate Blood Coagulation Factor

      Coagulation is the complex process by which activation of plasmatic haemostasis proteins ends up with the generation of fibrin. Most of the plasma coagulation proteins are synthesized in hepatocytes. The aim of this chapter

    • Secretion of Recombinant Human Insulin-Like Growth Factor I (IGF-I)

      The development of efficient recombinant protein production processes can be a critical factor in whether or not a pharmaceutical therapeutic protein can enter human clinical trials and ultimately the marketplace. This is especially true

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    北京孚博生物科技有限公司
    2025年07月18日询价
    ¥5382
    北京智杰方远科技有限公司
    2025年03月19日询价
    ¥4154
    上海益启生物科技有限公司
    2023年10月19日询价
    ¥2499
    上海优宁维生物科技股份有限公司
    2025年08月28日询价
    ¥2499
    爱必信(上海)生物科技有限公司
    2025年09月22日询价
    文献支持
    Recombinant Human Coagulation Factor VIIa
    ¥2415 - 53130